☆ 4.4 Article

A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants

CEPHALALGIA (2023)

Related references

Note: Only part of the references are listed.

Review Pharmacology & Pharmacy

Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review

Alicia Potter DeFalco et al.

Summary: Rimegepant orally disintegrating tablet is an effective option for treating migraines, providing rapid pain relief and symptom improvement, with potential adverse effects. It offers a promising therapeutic option for patients who cannot tolerate or have contraindications to other treatments.

ANNALS OF PHARMACOTHERAPY (2021)

Add to Collection

Article Medicine, General & Internal

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

Robert Croop et al.

Summary: Rimegepant was found to be effective for preventive treatment of migraine compared to placebo, with tolerability similar to that of placebo and no unexpected or serious safety issues noted.

LANCET (2021)

Add to Collection

Article Pharmacology & Pharmacy

Evaluating rimegepant for the treatment of migraine

Tessa de Vries et al.

Summary: Rimegepant, a small-molecule CGRP receptor antagonist, is well tolerated and effective for acute migraine treatment. However, its therapeutic gain is modest, and the long-term consequences of CGRP blockade require further research.

EXPERT OPINION ON PHARMACOTHERAPY (2021)

Add to Collection

Review Medicine, General & Internal

Migraine: epidemiology and systems of care

Messoud Ashina et al.

Summary: Migraine is a global neurovascular disorder that has negative impacts on patients, families, and society. Integrated and coordinated care systems can help reduce this burden. Low and middle-income countries face challenges in migraine care due to inadequate public health education and access to medication.

LANCET (2021)

Add to Collection

Article Clinical Neurology

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

Jessica Ailani et al.

Summary: This update aims to incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults. It provides practical recommendations based on expanded evidence base and emerging expert consensus, in the absence of a formal guideline.

HEADACHE (2021)

Add to Collection

Article Chemistry, Medicinal

Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success

Gene M. Dubowchik et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Add to Collection

Article Clinical Neurology

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy

Kathleen Mullin et al.

NEUROLOGY (2020)

Add to Collection

Review Pharmacology & Pharmacy

Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies

Danuta Szkutnik-Fiedler

PHARMACEUTICS (2020)

Add to Collection

Article Clinical Neurology

The Humanistic and Economic Burden of Migraine in Europe: A Cross-Sectional Survey in Five Countries

Michael J. Doane et al.

NEUROLOGY AND THERAPY (2020)

Add to Collection

Article Medicine, General & Internal

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

Robert Croop et al.

LANCET (2019)

Add to Collection

Article Medicine, General & Internal

Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine

Richard B. Lipton et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Clinical Neurology

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

Jes Olesen

CEPHALALGIA (2018)

Add to Collection

Review Physiology

PATHOPHYSIOLOGY OF MIGRAINE: A DISORDER OF SENSORY PROCESSING

Peter J. Goadsby et al.

PHYSIOLOGICAL REVIEWS (2017)

Add to Collection

Article Clinical Neurology

BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial

Ronald Marcus et al.

CEPHALALGIA (2014)

Add to Collection

Review Biochemistry & Molecular Biology

Systematic Evaluation of Dose Proportionality Studies in Clinical Pharmacokinetics

Yucheng Sheng et al.

CURRENT DRUG METABOLISM (2010)

Add to Collection

Review Pharmacology & Pharmacy

Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion

Juergen Hummel et al.

PHARMACEUTICAL STATISTICS (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.